Xgeva is used in men with advanced and metastatic prostate cancer with bone metastases for the prevention of developing additional skeletal-related events (not to be confused with bone mineral density). In a phase 3 trial, the 147 Study, evaluating denosumab (Xgeva) versus placebo 1,432 men with castrate-resistant prostate cancer demonstrated that Xgeva improved median bone [...]
ASCO has become a little more interesting for prostate cancer. Today's item is about a mega-analysis that confirms that the site of metastatic tumors will powerfully predict overall survival (OS) among men with metastatic castration resistant prostate cancer (mCRPC). Older and smaller studies had previously suggested that the metastatic site is prognostic for OS. This [...]
Men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) will eventually develop debilitating pain that impacts daily functioning and diminishes their quality of life. Based on prior studies, including a phase III trial, the superiority of denosumab over zoledronic acid (ZA) in delaying or preventing skeletal-related events (pathological fracture, radiation or surgery to the [...]
One of the more recent conversations surrounding prostate cancer treatment that we have been hearing involves the use of the anti-cholesterol drugs or statins. The conversation, whether or not statins might be a good treatment option for men with both localized disease and as an alternative to hormone treatment (ADT) for men with advanced prostate [...]
Men with castration-resistant prostate cancer (CRPC) and bone metastases (BM) will often have debilitating pain that impacts every aspect of their daily functioning thus significantly diminishing their quality of life (QoL). Finding the best drug or treatment to control the pain will allow men to have a more complete and fulfilling life as well as [...]
Would you be willing to trade off some survival time to lower your risk of developing bone metastases (BM)? Well, men in the UK and Sweden are willing. Men from the UK and Sweden with castrate resistant prostate cancer (CRPC) and at high risk for developing BM because they have been on androgen-deprivation (ADT) or [...]
From: the 2014 ASCO GU Meeting Abstract No: 35 Researchers have found in a randomized controlled trial of men with metastatic castration-resistant prostate cancer (mCRPC) the use of the treatment denosumab was superior to the more commonly used zoledronic acid (ZA) for reducing skeletal-related events (SRE). SREs are defined as a pathological fracture, surgery or [...]
The novel radiopharmaceutical radium-223 (Xofigo) appears to have long term safety with minimal adverse events. In an updated report, given at ASCO GU, on the ALSYMPCA trial of radium-233 (Xofigo), the researchers have found that there is no major safety issues identified within ~1.5 years after the completion of treatment in a population of men [...]
According to an analysis led by the Duke Cancer Institute, tasquinimo, an investigational prostate cancer treatment slows disease progression and may also increase survival, especially among men whose cancer has spread to the bones. This study that was published on Nov. 19, 2013, in the journal Clinical Cancer Research, shows that long-term survival and safety [...]
The number of cancer survivors is increasing, soon to be as many of 13 million of us in the world! Bones are often affected in cancer survivors, usually a result of bone metastases, or of anti-cancer therapies which can contribute to bone loss and fragility. Bone disease in cancer survivors can result both from the [...]
